ETF Holdings Breakdown of SMMT

SMMT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-29	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	421,221	USD 8,913,036
2025-09-29	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	421,221	USD 8,913,036
2025-09-29	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,771	USD 37,474 1.0%
Total =		844,213	USD 17,863,546

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with SMMT

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at Barclays

Equities researchers at Barclays assumed coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm set an “underweight” rating and a $13.00 price target on the stock. Barclays‘s target price suggests a potential downside of 32.40% from the company’s previous […] - 2025-09-19 02:50:56

Summit Therapeutics (NASDAQ:SMMT) Receives Buy Rating from HC Wainwright

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 176.40% from the company’s current price. […] - 2025-09-18 02:24:45

Analysts Set Summit Therapeutics PLC (NASDAQ:SMMT) PT at $33.79

Shares of Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have assigned a buy recommendation and one […] - 2025-09-15 02:30:25

Summit Therapeutics (NASDAQ:SMMT) Earns “Overweight” Rating from Cantor Fitzgerald

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research note issued on Monday,Benzinga reports. Other equities research analysts have also issued reports about the stock. UBS Group assumed coverage on shares of Summit Therapeutics in a research report on Tuesday, July 1st. […] - 2025-09-10 02:49:11

JMP Securities Reaffirms “Market Outperform” Rating for Summit Therapeutics (NASDAQ:SMMT)

JMP Securities reiterated their market outperform rating on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research note published on Tuesday morning,Benzinga reports. JMP Securities currently has a $40.00 target price on the stock. A number of other research analysts have also recently issued reports on SMMT. HC Wainwright reaffirmed a “buy” rating […] - 2025-08-20 03:12:43

Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $44.00 target price on the stock. SMMT has been the subject of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and set […] - 2025-08-18 03:01:11

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings Miss

Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report)’s stock price gapped down prior to trading on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $28.25, but opened at $27.06. Summit Therapeutics shares last traded at $27.40, with a volume of 985,195 shares. The company reported ($0.76) earnings per share for the […] - 2025-08-14 02:38:55

Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cwm LLC

Cwm LLC boosted its stake in Summit Therapeutics PLC (NASDAQ:SMMT – Free Report) by 3,455.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,671 shares of the company’s stock after acquiring an additional 1,624 shares during the period. Cwm LLC’s holdings in Summit […] - 2025-08-05 04:26:48

Commit To Buy Summit Therapeutics At $18, Earn 30.8% Annualized Using Options

Investors considering a purchase of Summit Therapeutics Inc (Symbol: SMMT) stock, but cautious about paying the going market price of $26.36/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in pa - 2025-08-01 12:38:43

Bank of New York Mellon Corp Raises Stake in Summit Therapeutics PLC (NASDAQ:SMMT)

Bank of New York Mellon Corp raised its stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT – Free Report) by 2.2% in the first quarter, Holdings Channel reports. The institutional investor owned 340,775 shares of the company’s stock after buying an additional 7,265 shares during the quarter. Bank of New York Mellon Corp’s holdings in […] - 2025-07-24 04:20:51

Summit Therapeutics Sees Unusually High Options Volume (NASDAQ:SMMT)

Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) was the target of unusually large options trading activity on Thursday. Traders acquired 10,819 call options on the stock. This is an increase of approximately 32% compared to the typical volume of 8,173 call options. Summit Therapeutics Stock Performance Summit Therapeutics stock opened at $24.35 on Friday. […] - 2025-07-04 02:38:56

Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $44.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 94.52% from the company’s current price. Several other research […] - 2025-07-03 04:26:50

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at Leerink Partners

Equities research analysts at Leerink Partners assumed coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage set an “underperform” rating and a $12.00 price target on the stock. Leerink Partners’ price target would indicate a potential downside of 40.48% from […] - 2025-06-13 02:22:52

Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of “Buy” from Analysts

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned a consensus rating of “Buy” from the eleven brokerages that are covering the firm, Marketbeat reports. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price […] - 2025-06-04 04:52:48

Summit Therapeutics (NASDAQ:SMMT) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a report published on Monday morning,Benzinga reports. They currently have a $40.00 price target on the stock. SMMT has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating on shares of Summit […] - 2025-06-03 02:52:45

Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?

Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down. - 2025-06-02 06:23:00

Summit: Phase III Trial Of Ivonescimab Plus Chemotherapy Shows Positive Results In EGFR-Mutant NSCLC

(RTTNews) - Summit Therapeutics Inc. (SMMT) announced Friday positive topline results from the Phase III clinical trial, HARMONi, evaluating ivonescimab plus chemotherapy in patients with EGFR-Mutant non-small cell lung cancer or NSCLC. - 2025-05-30 08:53:31

Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Purchased by Man Group plc

Man Group plc boosted its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 43.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,675 shares of the company’s stock after buying an additional 5,065 shares during the period. Man Group […] - 2025-05-28 04:59:01

Bank of America Corp DE Boosts Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)

Bank of America Corp DE boosted its position in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 10.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 431,568 shares of the company’s stock after purchasing an additional 40,908 shares during the period. […] - 2025-05-26 04:24:49

Northern Trust Corp Has $15.55 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)

Northern Trust Corp raised its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 1.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 871,402 shares of the company’s stock after buying an additional 14,075 shares during the quarter. Northern Trust Corp’s holdings in […] - 2025-05-15 05:00:50

StockNews.com Upgrades Summit Therapeutics (NASDAQ:SMMT) to Hold

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday. Several other research analysts have also commented on SMMT. Summit Redstone set a $35.00 target price on Summit Therapeutics in a research report on Wednesday, March 26th. HC […] - 2025-05-15 03:08:59

Summit Therapeutics (NASDAQ:SMMT) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) from a hold rating to a sell rating in a research note published on Monday morning. A number of other analysts have also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Summit Therapeutics in a report on Wednesday, April […] - 2025-05-06 02:36:50

SMMT Crosses Above Average Analyst Target

In recent trading, shares of Summit Therapeutics Inc (Symbol: SMMT) have crossed above the average analyst 12-month target price of $35.57, changing hands for $36.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade - 2025-04-25 08:00:49

JPMorgan Chase & Co. Sells 23,068 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)

JPMorgan Chase & Co. trimmed its position in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 14.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 139,581 shares of the company’s stock after selling 23,068 shares during the period. JPMorgan Chase & Co.’s holdings in Summit Therapeutics were worth $2,491,000 at the end of […] - 2025-04-24 04:24:52

Bank of Montreal Can Reduces Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)

Bank of Montreal Can lessened its position in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 13.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 84,225 shares of the company’s stock after selling 13,350 shares during the period. Bank of Montreal Can’s holdings in Summit Therapeutics were worth $1,503,000 at the end of […] - 2025-04-18 05:06:58

National Bank of Canada FI Acquires New Shares in Summit Therapeutics Inc. (NASDAQ:SMMT)

National Bank of Canada FI bought a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm bought 1,664 shares of the company’s stock, valued at approximately $30,000. Several other large investors also recently bought and sold shares of SMMT. XTX Topco Ltd raised its […] - 2025-04-13 05:44:55

Orion Portfolio Solutions LLC Makes New $193,000 Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)

Orion Portfolio Solutions LLC acquired a new stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 10,829 shares of the company’s stock, valued at approximately $193,000. Other institutional investors have also recently made […] - 2025-04-11 06:06:59

Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by Citigroup

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at Citigroup from a “neutral” rating to a “buy” rating in a report issued on Wednesday, MarketBeat.com reports. The firm currently has a $35.00 target price on the stock, up from their prior target price of $23.00. Citigroup’s target price would indicate […] - 2025-03-28 04:02:49

Summit Therapeutics (NASDAQ:SMMT) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. A number of other brokerages have also commented on SMMT. HC Wainwright reissued a “buy” rating and set a $44.00 price […] - 2025-03-24 04:34:45

Bank of New York Mellon Corp Has $5.95 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)

Bank of New York Mellon Corp increased its position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 33.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 333,510 shares of the company’s stock after purchasing an additional 84,117 shares during […] - 2025-03-17 05:15:01

Back to Listing

Disclaimer